

SKYEPHARMA PLC  
Form 6-K  
February 13, 2004

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of February, 2004

SkyePharma PLC

---

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

---

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-  
\_\_\_\_\_

---

**13 February 2004**

**SkyePharma PLC ("the Company")**

**Notification of Major Interest in Shares**

In accordance with the Companies Act 1985 (as amended) the Company was informed by Fidelity Investments on 12 February 2004 that FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries, both being non-beneficial holders ("Fidelity"), had increased their total holding to 87,676,918 ordinary shares of 10p each, representing 14.16% of the issued share capital of the Company. In addition Fidelity have informed the Company that they also hold 5,030,000 SkyePharma PLC 6% Convertible Bonds due 2005.

- ends -

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SkyePharma PLC**

By: /s/ Douglas Parkhill

Name: Douglas Parkhill

Title: Company Secretary

Date: February 13, 2004